tacrolimus

Tacrolimus is a lipid of Polyketides (PK) class. Tacrolimus is associated with abnormalities such as Renal glomerular disease. The involved functions are known as inhibitors, Fungicidal activity, Metabolic Inhibition, Excretory function and Dephosphorylation. Tacrolimus often locates in Hepatic, Mitochondrial matrix and Inner mitochondrial membrane. The associated genes with Tacrolimus are RHOA gene and BGN gene.

Cross Reference

Introduction

To understand associated biological information of tacrolimus, we collected biological information of abnormalities, associated pathways, cellular/molecular locations, biological functions, related genes/proteins, lipids and common seen animal/experimental models with organized paragraphs from literatures.

What diseases are associated with tacrolimus?

tacrolimus is suspected in Renal glomerular disease, Candidiasis, Mycoses, PARKINSON DISEASE, LATE-ONSET, Morphologically altered structure, Skin Diseases, Infectious and other diseases in descending order of the highest number of associated sentences.

Related references are mostly published in these journals:

Disease Cross reference Weighted score Related literature
Loading... please refresh the page if content is not showing up.

Possible diseases from mapped MeSH terms on references

We collected disease MeSH terms mapped to the references associated with tacrolimus

MeSH term MeSH ID Detail
Hemolysis D006461 131 associated lipids
Uremia D014511 33 associated lipids
Colitis, Ulcerative D003093 24 associated lipids
Stomach Ulcer D013276 75 associated lipids
Kidney Failure, Chronic D007676 51 associated lipids
Nocardia Infections D009617 6 associated lipids
Diarrhea D003967 32 associated lipids
Diabetes Mellitus D003920 90 associated lipids
Graft Occlusion, Vascular D006083 11 associated lipids
Hypercalcemia D006934 13 associated lipids
Neovascularization, Pathologic D009389 39 associated lipids
Adenocarcinoma D000230 166 associated lipids
Dermatitis, Contact D003877 59 associated lipids
Bacterial Infections D001424 21 associated lipids
Pain D010146 64 associated lipids
Autoimmune Diseases D001327 27 associated lipids
Lupus Erythematosus, Systemic D008180 43 associated lipids
Genital Diseases, Female D005831 7 associated lipids
Mouth Diseases D009059 5 associated lipids
Meningococcal Infections D008589 3 associated lipids
Lung Diseases D008171 37 associated lipids
Lung Neoplasms D008175 171 associated lipids
Mycobacterium Infections D009164 7 associated lipids
Sarcoidosis D012507 13 associated lipids
Hepatolenticular Degeneration D006527 3 associated lipids
Hyperglycemia D006943 21 associated lipids
Carcinoma, Squamous Cell D002294 14 associated lipids
Skin Neoplasms D012878 12 associated lipids
Burns D002056 34 associated lipids
Inflammation D007249 119 associated lipids
Inflammatory Bowel Diseases D015212 9 associated lipids
Reperfusion Injury D015427 65 associated lipids
Colitis D003092 69 associated lipids
Colonic Neoplasms D003110 161 associated lipids
Diabetes Mellitus, Type 1 D003922 56 associated lipids
Diabetes Mellitus, Type 2 D003924 87 associated lipids
Fatty Liver D005234 48 associated lipids
Cataract D002386 34 associated lipids
Diabetes Mellitus, Experimental D003921 85 associated lipids
Body Weight D001835 333 associated lipids
Edema D004487 152 associated lipids
Precancerous Conditions D011230 48 associated lipids
Postoperative Complications D011183 5 associated lipids
Arthritis D001168 41 associated lipids
Arthritis, Experimental D001169 24 associated lipids
Surgical Wound Infection D013530 7 associated lipids
Neoplasm Recurrence, Local D009364 5 associated lipids
Osteonecrosis D010020 5 associated lipids
Hypotension D007022 41 associated lipids
Acute Kidney Injury D058186 34 associated lipids
Per page 10 20 50 100 | Total 613

PubChem Associated disorders and diseases

What pathways are associated with tacrolimus

There are no associated biomedical information in the current reference collection.

PubChem Biomolecular Interactions and Pathways

Link to PubChem Biomolecular Interactions and Pathways

What cellular locations are associated with tacrolimus?

Related references are published most in these journals:

Location Cross reference Weighted score Related literatures
Loading... please refresh the page if content is not showing up.

What functions are associated with tacrolimus?


Related references are published most in these journals:

Function Cross reference Weighted score Related literatures

What lipids are associated with tacrolimus?

Related references are published most in these journals:

Lipid concept Cross reference Weighted score Related literatures
Loading... please refresh the page if content is not showing up.

What genes are associated with tacrolimus?

Related references are published most in these journals:


Gene Cross reference Weighted score Related literatures

What common seen animal models are associated with tacrolimus?

There are no associated biomedical information in the current reference collection.

NCBI Entrez Crosslinks

All references with tacrolimus

Download all related citations
Per page 10 20 50 100 | Total 15051
Authors Title Published Journal PubMed Link
Rhu J et al. Clinical Implication of Mycophenolic Acid Trough Concentration Monitoring in Kidney Transplant Patients on a Tacrolimus Triple Maintenance Regimen: A Single-Center Experience. 2017 Ann. Transplant. pmid:29180612
Rehman S et al. Effect of different tacrolimus levels on early outcomes after kidney transplantation. 2014 Ann. Transplant. pmid:24509826
Herden U et al. Early Initiation of Everolimus After Liver Transplantation: A Single-Center Experience. 2016 Ann. Transplant. pmid:26842532
Ogura Y et al. Early Conversion From Twice-Daily Tacrolimus to Prolonged-Release Tacrolimus in Liver Transplantation: A Single-Center Experience. 2016 Ann. Transplant. pmid:27432248
Schnitzbauer AA et al. Delayed bottom-up and amended simple method of dosing with once-daily tacrolimus application to achieve stable trough levels in liver transplantation. 2015 Ann. Transplant. pmid:25553853
Van Laecke S et al. Effect of Magnesium Supplements on Insulin Secretion After Kidney Transplantation: A Randomized Controlled Trial. 2017 Ann. Transplant. pmid:28848225
Holechek MJ Medication review: FK 506. 1991 ANNA J pmid:1708982
Schmid FX Prolyl isomerase: enzymatic catalysis of slow protein-folding reactions. 1993 Annu Rev Biophys Biomol Struct pmid:7688608
Sigal NH and Dumont FJ Cyclosporin A, FK-506, and rapamycin: pharmacologic probes of lymphocyte signal transduction. 1992 Annu. Rev. Immunol. pmid:1375473
Tzakis AG et al. Intestinal transplantation. 1994 Annu. Rev. Med. pmid:7515221
Hanauer SB and Dassopoulos T Evolving treatment strategies for inflammatory bowel disease. 2001 Annu. Rev. Med. pmid:11160781
Pratt WB The role of the hsp90-based chaperone system in signal transduction by nuclear receptors and receptors signaling via MAP kinase. 1997 Annu. Rev. Pharmacol. Toxicol. pmid:9131255
Nikitin AV [Mechanisms of nephrotoxic action of immunodepressants, calcineurine inhibitors]. 2014 Antibiot. Khimioter. pmid:25051716
Romano S et al. FK506 binding proteins as targets in anticancer therapy. 2010 Anticancer Agents Med Chem pmid:21182472
Epand RF and Epand RM The new potent immunosuppressant FK-506 reverses multidrug resistance in Chinese hamster ovary cells. 1991 Anticancer Drug Des. pmid:1714737
Jachez B et al. Reversion of the P-glycoprotein-mediated multidrug resistance of cancer cells by FK-506 derivatives. 1993 Anticancer Drugs pmid:7683935
Yamamoto M et al. Cyclosporin A and FK506 reverse anthracycline resistance by altering the cell cycle. 1995 Anticancer Drugs pmid:7579561
Pourtier-Manzanedo A et al. FK-506 (fujimycin) reverses the multidrug resistance of tumor cells in vitro. 1991 Anticancer Drugs pmid:1724925
Mizuno K et al. Modulation of multidrug resistance by immunosuppressive agents: cyclosporin analogues, FK506 and mizoribine. 1992 Jan-Feb Anticancer Res. pmid:1373592
Pinsk V et al. Complete Reversion of Familial Adenomatous Polyposis Phenotype Associated with Tacrolimus and Mycophenolate Mofetil Treatment Following Kidney Transplantation. 2017 Anticancer Res. pmid:28551651
Kalas W et al. FK506 restores sensitivity of thymic lymphomas to calcium-mediated apoptosis and the inducible expression of Fas ligand. 2003 Mar-Apr Anticancer Res. pmid:12820430
Harada N et al. Serum Asunaprevir and Daclatasvir Concentrations and Outcomes in Patients with Recurrent Hepatitis C Who Have Undergone Living Donor Liver Transplantation. 2018 Anticancer Res. pmid:30194210
Ling G et al. Mycophenolate Mofetil Alone and in Combination with Tacrolimus Inhibits the Proliferation of HT-29 Human Colonic Adenocarcinoma Cell Line and Might Interfere with Colonic Tumorigenesis. 2018 Anticancer Res. pmid:29848681
Morisaki T et al. A combination of cyclosporin-A (CsA) and interferon-gamma (INF-gamma) induces apoptosis in human gastric carcinoma cells. 2000 Sep- Oct Anticancer Res. pmid:11131636
Gornet JM et al. Severe CPT-11-induced diarrhea in presence of FK-506 following liver transplantation for hepatocellular carcinoma. 2001 Nov-Dec Anticancer Res. pmid:11911319
Gauthier C et al. Functional similarities and differences between Candida albicans Cdr1p and Cdr2p transporters. 2003 Antimicrob. Agents Chemother. pmid:12709320
Del Poeta M et al. Synergistic antifungal activities of bafilomycin A(1), fluconazole, and the pneumocandin MK-0991/caspofungin acetate (L-743,873) with calcineurin inhibitors FK506 and L-685,818 against Cryptococcus neoformans. 2000 Antimicrob. Agents Chemother. pmid:10681348
Steinbach WJ et al. Calcineurin inhibition or mutation enhances cell wall inhibitors against Aspergillus fumigatus. 2007 Antimicrob. Agents Chemother. pmid:17502415
Morikawa K et al. Immunomodulatory effects of three macrolides, midecamycin acetate, josamycin, and clarithromycin, on human T-lymphocyte function in vitro. 1994 Antimicrob. Agents Chemother. pmid:7532933
Steinbach WJ et al. In vitro interactions between antifungals and immunosuppressants against Aspergillus fumigatus. 2004 Antimicrob. Agents Chemother. pmid:15105118
Lamoth F et al. In vitro activity of calcineurin and heat shock protein 90 Inhibitors against Aspergillus fumigatus azole- and echinocandin-resistant strains. 2013 Antimicrob. Agents Chemother. pmid:23165466
Onyewu C et al. Ergosterol biosynthesis inhibitors become fungicidal when combined with calcineurin inhibitors against Candida albicans, Candida glabrata, and Candida krusei. 2003 Antimicrob. Agents Chemother. pmid:12604527
Fortwendel JR et al. Differential effects of inhibiting chitin and 1,3-{beta}-D-glucan synthesis in ras and calcineurin mutants of Aspergillus fumigatus. 2009 Antimicrob. Agents Chemother. pmid:19015336
Lamping E et al. Abc1p is a multidrug efflux transporter that tips the balance in favor of innate azole resistance in Candida krusei. 2009 Antimicrob. Agents Chemother. pmid:19015352
Reedy JL et al. Immunotherapy with tacrolimus (FK506) does not select for resistance to calcineurin inhibitors in Candida albicans isolates from liver transplant patients. 2006 Antimicrob. Agents Chemother. pmid:16569889
Katiyar SK et al. Fks1 and Fks2 are functionally redundant but differentially regulated in Candida glabrata: implications for echinocandin resistance. 2012 Antimicrob. Agents Chemother. pmid:23027185
Vaes M et al. Therapeutic drug monitoring of posaconazole in patients with acute myeloid leukemia or myelodysplastic syndrome. 2012 Antimicrob. Agents Chemother. pmid:23027198
Zhuang D et al. Effect of calcineurin inhibitors on posaconazole blood levels as measured by the MVista microbiological assay. 2008 Antimicrob. Agents Chemother. pmid:18025114
Kontoyiannis DP et al. Calcineurin inhibitor agents interact synergistically with antifungal agents in vitro against Cryptococcus neoformans isolates: correlation with outcome in solid organ transplant recipients with cryptococcosis. 2008 Antimicrob. Agents Chemother. pmid:18070977
Ricardo E et al. In vivo and in vitro acquisition of resistance to voriconazole by Candida krusei. 2014 Antimicrob. Agents Chemother. pmid:24867987
Coilly A et al. Practical management of boceprevir and immunosuppressive therapy in liver transplant recipients with hepatitis C virus recurrence. 2012 Antimicrob. Agents Chemother. pmid:22908172
Gao L and Sun Y In vitro interactions of antifungal agents and tacrolimus against Aspergillus biofilms. 2015 Antimicrob. Agents Chemother. pmid:26303797
Uppuluri P et al. Synergistic effect of calcineurin inhibitors and fluconazole against Candida albicans biofilms. 2008 Antimicrob. Agents Chemother. pmid:18180354
Odom A et al. The immunosuppressant FK506 and its nonimmunosuppressive analog L-685,818 are toxic to Cryptococcus neoformans by inhibition of a common target protein. 1997 Antimicrob. Agents Chemother. pmid:8980772
Steinbach WJ et al. In vitro interactions between antifungals and immunosuppressants against Aspergillus fumigatus isolates from transplant and nontransplant patients. 2004 Antimicrob. Agents Chemother. pmid:15561883
Aoki Y and Kao PN Erythromycin inhibits transcriptional activation of NF-kappaB, but not NFAT, through calcineurin-independent signaling in T cells. 1999 Antimicrob. Agents Chemother. pmid:10543746
Dannaoui E et al. In vitro interactions between antifungals and immunosuppressive drugs against zygomycetes. 2009 Antimicrob. Agents Chemother. pmid:19451295
Rivosecchi RM et al. Effects of Isavuconazole on the Plasma Concentrations of Tacrolimus among Solid-Organ Transplant Patients. 2017 Antimicrob. Agents Chemother. pmid:28674051
Rosenwirth B et al. Inhibition of human immunodeficiency virus type 1 replication by SDZ NIM 811, a nonimmunosuppressive cyclosporine analog. 1994 Antimicrob. Agents Chemother. pmid:7527198
Venkataramanan R et al. Voriconazole inhibition of the metabolism of tacrolimus in a liver transplant recipient and in human liver microsomes. 2002 Antimicrob. Agents Chemother. pmid:12183280